What's Happening?
Aptar Pharma, a leader in drug delivery technologies, announced progress on its research contract with the U.S. FDA, focusing on transitioning metered-dose inhalers (MDIs) to next-generation propellants (NGPs). The contract, awarded in September 2023,
aims to identify target product profiles for NGP MDIs to match existing MDIs' quality attributes. Research activities include experimental designs to evaluate drug formulation factors, computational modeling of aerosol physics, and propellant properties analysis. Aptar Pharma has shared scientific learnings with the FDA, supporting the agency's initiatives to understand NGP MDIs. The research is not intended for specific product support but aims to advance scientific understanding in the field.
Why It's Important?
The research conducted by Aptar Pharma is significant as it addresses the industry's need to transition to more sustainable inhaler propellants. Current MDIs contribute to environmental concerns due to their propellant gases. By advancing NGPs, Aptar Pharma supports the development of eco-friendly inhalation products, aligning with global sustainability goals. This research could lead to improved inhaler designs, enhancing patient outcomes and reducing environmental impact. Aptar Pharma's work demonstrates its commitment to innovation and sustainability in drug delivery, potentially influencing industry standards and practices.
What's Next?
Aptar Pharma plans to continue its research, with potential contract extensions including exploratory pharmacokinetic studies. Scientific outcomes will be presented at major conferences, such as the Respiratory Drug Delivery conference in May 2026. Peer-reviewed publications are expected to disseminate findings further. Aptar Pharma's collaboration with the FDA and its scientific teams will continue to drive advancements in inhaler technology, supporting the transition to next-generation propellants and improving patient care.
